HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Clinical trial NCT04732416 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04732416
- Sponsor
- Hanmi Pharmaceutical Company Limited
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-05-05
- Primary completion
- 2026-07-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.